Meet Dr. Yasir Elamin

I sat down with Dr. Yasir Elamin to get his thoughts on his presentation at ASCO regarding patient reported outcomes and health-related quality of life with Taletrectinib in advanced ROS1 non-small cell lung cancer (NSCLC) from the TRUST-II Study.